Sick sinus syndrome in chronic chagas heart disease

Hernández-Pieretti, O.; Lozano-Wilson, JoséH.; Urbina-Quintana, A.; Villoria, Guillermo; Hernández, Maria I. de; E, Gómez-Amundarain

doi:10.1016/0002-9149(74)90839-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cabe notar que los pacientes chagásicos tuvieron valores más bajos de la tensión arterial y del pulso, incluso después de excluirse los trastornos del ritmo que se describen en la enfermedad de Chagas, como bradicardia sinusal, enfermedad del nodo senoauricular y bloqueos auriculoventriculares (38). Esto sugiere algún tipo de trastorno del sistema nervioso autónomo (39,40), tal como el que se ha descrito en los pacientes con insuficiencia cardíaca (41), cardiopatía isquémica (42) y diabetes (43).…”

Section: Cuadro 2 Relación De Los Títulos Séricos De Anticuerpos Antunclassified

Títulos de anticuerpos antisulfátido en pacientes con cardiopatía chagásica crónica y con otras formas de cardiopatía

García¹,

Avila²,

Rojas³

et al. 1998

Rev Panam Salud Publica

View full text Add to dashboard Cite

A specific treatment for Chagas' disease has not yet been discovered, even though the condition is endemic in large parts of the Region of the Americas. Earlier studies have addressed the possibility that the sulfatide galactocerebroside in Trypanosoma cruzi behaves as an immunogen involved in the production of the high antisulfatide antibody levels found in patients with chronic infestation with the parasite. This may be an important factor in the pathogenesis of the cardiac symptoms and peripheral neuropathy seen in Chagas' disease, which is the most important cause of myocarditis in Central and South America and the second most important cause of heart failure in several of the countries located in these subregions. The present study was conducted in order to ascertain whether patients with Chagas' disease and other patients not afflicted with the ailment differ insofar as the presence of antibodies against sulfatide is concerned, and it describes antisulfatide antibody levels in 124 hospital patients (74 men and 50 women) between the ages of 15 and 94 who were in the cardiology unit of Vargas Hospital in Caracas from 1 July to 30 June 1995. Antisulfatide antibody titers were determined by means of enzyme-linked immunosorbent assays (ELISA), and the antigen employed was sulfatide cerebroside obtained from bovine brain tissue. Of the 124 patients under study, 39 (31.5%) suffered from Chagas' disease and had antisulfatide antibody levels higher than those detected in patients without Chagas (P = 0.0298) and in 28 seemingly healthy controls (P = 0.0035). Serum levels of antisulfatide antibodies in patients with other forms of heart disease were also compared with those seen in the control group, and significantly higher levels were found in patients with acute ischemic heart disease (P = 0.0049), rheumatic valvular heart disease (P = 0.0075), chronic ischemic heart disease (P = 0.0464) and bradiarrythmias (P = 0.0157), and significantly lower ones in subjects with hypertensive heart disease (P = 0.0367). These antibody levels showed no correlation with clinical or paraclinical variables indicative of the degree of cardiac compromise. Our results support the notion that antibodies against sulfatide may play a role in the pathogenesis of Chagas' cardiomyopathy and other forms of heart disease and should be further studied in an effort to determine their potential role in these processes.

show abstract

Section: Cuadro 2 Relación De Los Títulos Séricos De Anticuerpos Antunclassified